Re-Defining High Risk COPD with Parameter Response Mapping Based on Machine Learning Models

Int J Chron Obstruct Pulmon Dis. 2022 Oct 4:17:2471-2483. doi: 10.2147/COPD.S369904. eCollection 2022.

Abstract

Purpose: To explore optimal threshold of FEV1% predicted value (FEV1%pre) for high-risk chronic obstructive pulmonary disease (COPD) using the parameter response mapping (PRM) based on machine learning classification model.

Patients and methods: A total of 561 consecutive non-COPD subjects who were screened for chest diseases in our hospital between August and October 2018 and who had complete questionnaire surveys, pulmonary function tests (PFT), and paired respiratory chest CT scans were enrolled retrospectively. The CT quantitative parameter for small airway remodeling was PRM, and 72 parameters were obtained at the levels of whole lung, left and right lung, and five lobes. To identify a more reasonable thresholds of FEV1% predicted value for distinguishing high-risk COPD patients from the normal, 80 thresholds from 50% to 129% were taken with a partition of 1% to establish a random forest classification model under each threshold, such that novel PFT-parameter-based high-risk criteria would be more consistent with the PRM-based machine learning classification model.

Results: Machine learning-based PRM showed that consistency between PRM parameters and PFT was better able to distinguish high-risk COPD from the normal, with an AUC of 0.84 when the threshold was 72%. When the threshold was 80%, the AUC was 0.72 and when the threshold was 95%, the AUC was 0.64.

Conclusion: Machine learning-based PRM is feasible for redefining high-risk COPD, and setting the optimal FEV1% predicted value lays the foundation for redefining high-risk COPD diagnosis.

Keywords: artificial intelligence; chronic obstructive pulmonary disease; computed tomography; pulmonary function test; quantitative imaging.

MeSH terms

  • Humans
  • Lung / diagnostic imaging
  • Machine Learning
  • Pulmonary Disease, Chronic Obstructive* / diagnostic imaging
  • Respiratory Function Tests
  • Retrospective Studies

Grants and funding

This work was supported by the the National Natural Science Foundation of China [grant number 81871321, 81930049, 82171926], National Key R&D Program of China [grant number 2022YFC2010002, 2022YFC2010000], The clinical Innovative Project of Shanghai Changzheng Hospital [grant number 2020YLCYJ-Y24]; The program of Science and Technology Commission of Shanghai Municipality [grant number 21DZ2202600], The program of Science and Technology Innovation Action Plan of Shanghai Municipality [grant number 19411951300], Shanghai Sailing Program [grant number 20YF1449000] and Pyramid Talent Project of Shanghai Changzheng Hospital.